Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
Revisado por: José Antonio Couceiro Gianzo
Grupo de trabajo: Infecciones Respiratorias
Referencia: Lin GL, Drysdale SB, Snape MD, et al. Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus. Nat Commun. 2024 Mar 16;15(1):2379. doi: 10.1038/s41467-024-46648-3
The Contribution of Viruses and Bacteria to Childhood Community-Acquired Pneumonia: 11-Year Observational Study From Norway
Revisado por: Enrique Otheo de Tejada
Grupo de trabajo: Infecciones Respiratorias
Referencia: Smyrnaios A, Risnes K, Krokstad S, Nordbø SA, Heimdal I, Christensen A, Døllner H. The Contribution of Viruses and Bacteria to Childhood Community-Acquired Pneumonia: 11-Year Observational Study From Norway. Pediatr Infect Dis J. 2023 Jun 1;42(6):456-460.
Epidemiología reciente de las infecciones por metapneumovirus humano
Revisado por: Cristina Calvo
Grupo de trabajo: Infecciones Respiratorias
Referencia: Steinberg R, Marty V, Korten I, Aebi C, Latzin P, Agyeman PK. Epidemiology and Clinical Characteristics of Human Metapneumovirus Infections in Hospitalized Children in Two Consecutive Postpandemic Years. Pediatr Infect Dis J. 2024 Apr 1;43(4):e141-e144
Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota
Revisado por: Carlos Rodrigo Gonzalo de Liria
Grupo de trabajo: Infecciones Respiratorias
Referencia: Koenen MH, de Groot RCA, de Steenhuijsen Piters WAA, et al. Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota. EBioMedicine. 2023 Dec;98:104868. doi: 10.1016/j.ebiom.2023.104868.
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
Revisado por: Marta Cruz Cañete
Grupo de trabajo: Infecciones Respiratorias
Referencia: López-Lacort Mónica, Muñoz-Quiles Cintia, Mira-Iglesias Ainara, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):pii=2400046. https://doi.org/10.2807/1560-7917.ES.2024.29.6.2400046
Preexposure Prophylaxis Provision among Adolescents: 2018 to 2021
Revisado por: María Espiau
Grupo de trabajo: Infección por VIH
Referencia: Kimball AA, Zhu W, Leonard J, et al. HIV Preexposure Prophylaxis Provision among Adolescents: 2018 to 2021. Pediatrics. 2023;152(5):e2023062599.
A phase III randomised controlled trial evaluating the malaria vaccine 1 candidate R21/Matrix-M™™ in African children
Revisado por: Rosauro Varo Cobos
Grupo de trabajo: Patología Importada
Referencia: Datoo M, Dicko A, Tinto H et al. A phase III randomised controlled trial evaluating the malaria vaccine 1 candidate R21/Matrix-M™™ in African children. Lancet.
Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
Revisado por: Laura Francisco González
Grupo de trabajo: Infecciones Respiratorias
Referencia: Baker, Jeffery B. ; Block, Stanley L.; Cagas, Steven E.; Macutkiewicz, Laura Burleigh; Collins, Colleen; Sadeghi, Mitra Sarkar, Sriparna; Williams, Sarah. Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study. The Pediatric Infectious Disease Journal. 2023;42:983-989.
A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children
Revisado por: David López Martín
Grupo de trabajo: Infecciones bacterianas
Referencia: Frenck, R, Laudat F, Liang J, Giordano-Schmidt D, Jansen K, Gruber W, et Al. A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children. Pediatr Infect Dis J 2023;42:1045–1050
